Ask AI
ProCE Banner Activity

Novel RAS-Targeted Therapies for Pancreatic Ductal Adenocarcinoma

Slideset

In these downloadable slides, experts outline the evolving field of RAS-targeted therapies for metastatic PDAC, including novel mechanisms of action.

Released: April 15, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Revolution Medicines, Inc.

Revolution Medicines, Inc.

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with pancreatic cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply molecular profiling to identify actionable RAS(ON) alterations in patients with advanced pancreatic ductal adenocarcinoma (PDAC)

  • Analyze clinical data from key trials evaluating emerging RAS-targeted agents for metastatic PDAC

  • Refer eligible patients with PDAC to clinical trials of investigational RAS(ON)–targeted agents